Spyre Therapeutics
SYRE
SYRE
71 hedge funds and large institutions have $159M invested in Spyre Therapeutics in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
71
Holders Change
+11
Holders Change %
+18.33%
% of All Funds
1.54%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
17
Increased
25
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$4.03M |
| 2 |
Goldman Sachs
New York
|
+$3.11M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$3.03M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.02M |
| 5 |
ACM
Aisling Capital Management
New York
|
+$2.84M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$4.63M |
| 2 |
Man Group
London,
United Kingdom
|
-$276K |
| 3 |
Squarepoint
New York
|
-$167K |
| 4 |
Morgan Stanley
New York
|
-$147K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$116K |
